menu
    • menu
    [{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbit Discovery \/ Endevica Bio","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Endevica Bio"},{"orgOrder":0,"company":"Evotec","sponsor":"Inserm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Inserm","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Inserm"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Driehaus Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Driehaus Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ Driehaus Capital Management"},{"orgOrder":0,"company":"Embark Biotech","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Embark Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Embark Biotech \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Embark Biotech \/ Novo Nordisk"},{"orgOrder":0,"company":"Kallyope","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kallyope \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/ Novo Nordisk"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regeneron Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Regeneron Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Septerna","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Septerna","amount2":2.2000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.2000000000000002,"dosageForm":"Oral","sponsorNew":"Septerna \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Septerna \/ Novo Nordisk"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Septerna

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Septerna

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Novo Nordisk

                            Deal Size : $2,200.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Septerna and Novo Nordisk Partner on Oral Drugs for Obesity and Metabolic Diseases

                            Details : The companies will initially commence development programs for potential therapies targeting one or more GPCRs to discover and develop oral small-molecule medicines for obesity.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $200.0 million

                            May 14, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Novo Nordisk

                            Deal Size : $2,200.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kallyope

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Kallyope

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Novo Nordisk

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kallyope Announces License Agreement with Novo Nordisk

                            Details : Under the terms of the license agreement, Novo Nordisk will discover novel peptide therapeutics including as a potential new mechanism for the treatment of obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 09, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Novo Nordisk

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Confo Therapeutics

                            Belgium arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Confo Therapeutics

                            Belgium arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Driehaus Capital Management

                            Deal Size : $65.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Confo Secures EUR 60M Series B for GPCR-Modulating Therapies

                            Details : The proceeds will be used to advance wholly-owned programs, including molecules targeting GPR75, which is being evaluated in the early-stage clinical trial studies for obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 25, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Driehaus Capital Management

                            Deal Size : $65.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evotec

                            Germany arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Evotec

                            Germany arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Inserm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evotec, Inserm, Lille University Hospital Collaborate on Therapeutic Targets in Obesity

                            Details : The collaboration aims to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases by leveraging PanOmics technologies of Evotech.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Inserm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Deep Apple Therapeutics

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Deep Apple Therapeutics

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Apple Tree Partners

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-B...

                            Details : The net proceeds will be used for advancing multiple novel small molecule therapeutics focused on GPCR modulators, a proven target class with applications in metabolic disorders, inflammation, immunology, and endocrine diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 14, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Apple Tree Partners

                            Deal Size : $52.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Embark Biotech

                            Country arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Embark Biotech

                            Country arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Novo Nordisk

                            Deal Size : $511.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novo Nordisk Acquires Embark Biotech, Including its Lead Asset Targeting Obesity and Other Cardiometabolic Dis...

                            Details : Under the acquisition, Novo Nordisk receives the full rights to develop and commercialize the lead program to treat obesity and related co-morbidities.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $16.2 million

                            August 30, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Novo Nordisk

                            Deal Size : $511.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Orbit Discovery

                            Europe arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Orbit Discovery

                            Europe arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Endevica Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeut...

                            Details : The collaboration aims to accelerate Endevica’s development of advanced GPCR-targeting therapeutics on receptor sets both novel and complimentary to its lead compound to creat first-in-class therapeutics for cachexia caused by cancer and other chronic ...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Endevica Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed

                            Regeneron Pharmaceuticals

                            U.S.A arrow
                            KY/TN Water Professionals
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AstraZeneca Collaborate with Regeneron to Research, Develop & Commercialise

                            Details : AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 27, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth